Contract Development and Manufacturing Organizations (CDMO) Stocks
Third-party service providers and manufacturing partners facilitate the high-capital stages of drug development, clinical trials, and commercial-scale production for biotechnology and pharmaceutical entities.
As of Oct 23, 2026, Contract Development and Manufacturing Organizations (CDMO) has 29 US-listed companies worth $437B combined. The median member moved +1.6% over the past week; CRL led among the 25 largest at +15.1% and MGNX trailed at -30.8%.
Companies in Contract Development and Manufacturing Organizations (CDMO)
- TMO – Thermo Fisher Scientific Inc, $249B
- IQV – IQVIA Holdings Inc, $45.8B
- WST – West Pharmaceutical Services Inc, $27.7B
- LH – Laboratory Corporation of America Holdings, $26.7B
- MEDP – Medpace Holdings Inc, $18.3B
- CRL – Charles River Laboratories, $16.6B
- ICLR – ICON PLC, $14.3B
- AVTR – Avantor Inc, $11.7B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- STVN – Stevanato Group SpA, $5.5B
- ITGR – Integer Holdings Corp, $4.3B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- FTRE – Fortrea Holdings Inc., $2.1B
- EVO – Evotec SE ADR, $478M
- TKNO – Alpha Teknova Inc, $468M
- LFCR – Lifecore Biomedical Inc., $248M
- MGNX – MacroGenics Inc, $218M
- CDXS – Codexis Inc, $145M
- HYFT – ImmunoPrecise Antibodies Ltd., $60.8M
- COSM – Cosmos Health Inc., $33.3M
- DYAI – Dyadic International Inc, $17.8M
- PLUR – Pluri Inc., $12.5M
- BMRA – Biomerica Inc, $8.6M
- BGLC – BioNexus Gene Lab Corp Common stock, $3.6M
- ORGS – Orgenesis Inc, $3.4M
- VIVS – VivoSim Labs, Inc., $2.6M
- SCNI – Scinai Immunotherapeutics Ltd, $826,686
- SCPX – Scorpius Holdings Inc, $12,228
- THMO – Thermogenesis Holdings Inc, $1,584